TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01296113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Pemetrexed + Carboplatin~On D1 of a 21-day cycle:~* Pemetrexed 500 mg/m² IV in 10 minutes followed 30 minutes later by:~* Carboplatin AUC 5 in 30 minutes in 100 ml sterile water or 5% glucose or physiological serum. The carboplatin dose will be calculated by the Calvert formula with a target AUC of 5 mg/mL.min as follows:~Carboplatin dose in mg = 5 x (GFR + 25) GFR is estimated according to the MDRD equation for creatinine clearance~• 4 cycles total
Study: NCT02344095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: weekly paclitaxel
Description: Patients are treated with weekly paclitaxel 70mg/m2 (IV) on day 1, 8, and 15 at an intervals of 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: weekly cisplatin
Description: Patients are treated with weekly cisplatin 40mg/m2 (IV) on day 1, 8, and 15 at an intervals of 4 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oncothermia
Description: Thermotherapy is performed by applying oncothermia (EHY 2000) probe on the part of body where tumor is located and delivering energy. It is performed on day 1, 4, 8, 11, 15, 18, 21, and 24 (8 times in total every cycle). Oncothermia can be performed a day earlier than scheduled day or a day later than scheduled day. With tumors at multiple sites, oncothermia is performed several times changing sites that apply probe and type of probes.~- It takes 60 minutes to treat a site for oncothermia. Energy is gradually increased from 60W to 140W.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oncothermia
Description: Thermotherapy is performed by applying oncothermia (EHY 2000) probe on the part of body where tumor is located and delivering energy. It is performed on day 1, 4, 8, 11, 15, 18, 21, and 24 (8 times in total every cycle). Oncothermia can be performed a day earlier than scheduled day or a day later than scheduled day. With tumors at multiple sites, oncothermia is performed several times changing sites that apply probe and type of probes.~- It takes 60 minutes to treat a site for oncothermia. Energy is gradually increased from 60W to 140W.
Study: NCT02058407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2793660 solution
Description: Clear, colourless solution at a unit dose strength of 0.1 mg/mL, in a glass bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2793660 solution
Description: Clear, colourless solution at a unit dose strength of 0.1 mg/mL, in a glass bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2793660 capsule
Description: Size zero swedish orange capsule at a unit dose of 3 mg, 10 mg, 20 mg and 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2793660 capsule
Description: Size zero swedish orange capsule at a unit dose of 3 mg, 10 mg, 20 mg and 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2793660 capsule
Description: Size zero swedish orange capsule at a unit dose of 3 mg, 10 mg, 20 mg and 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2793660 capsule
Description: Size zero swedish orange capsule at a unit dose of 3 mg, 10 mg, 20 mg and 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo solution
Description: Matching placebo to GSK2793660 solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo solution
Description: Matching placebo to GSK2793660 solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Matching placebo to GSK2793660 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Matching placebo to GSK2793660 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Matching placebo to GSK2793660 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Matching placebo to GSK2793660 capsule
Study: NCT01631929

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One bag
Description: Infusion of dextrose and electrolytes using one bag

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two bags
Description: Using 2 bags with different solutions with the same electrolyte content but different dextrose concentration (0% and 10%), administered simultaneously through the same intravenous line.
Study: NCT02123511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylcysteine
Description: Oral rinse

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral rinse

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT02105142

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ADHD Group Visits
Description: Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ADHD Group Visits plus Online Discussion Portal
Description: Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians. Parent participants will be granted access to the online discussion portal to allow for communication in between in-person group visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer Decision Support
Description: ADHD Module of the Child Health Improvement through Computer Automation (CHICA) system Designed to facilitate physician adherence to clinical care guidelines for ADHD identification and chronic care management
Study: NCT03426852

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00049309

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flaxseed

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flaxseed
Study: NCT00676637

Intervention type: DRUG
Intervention: Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)
Description: One drop in study eye(s) once daily in the evening for four months

Intervention type: DEVICE
Intervention: Travalert Dosing Aid
Description: Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence
Study: NCT02143778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Methacetin Breath Test
Description: 13C labelled methacetin solution for breath test monitoring
Study: NCT04174157

Intervention type: DRUG
Intervention: Zolgensma
Description: Zolgensma will be given to patients as per normal clinical practice and clinical care will not be mandated by the protocol. As such, the decision to prescribe Zolgensma is separate from the decision to include the patient in this study
Study: NCT00000249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20% N2O
Description: 20% inhaled N2O

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% N2O
Description: 30% inhaled N2O
Study: NCT01218256

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise training
Description: aerobic endurance training (cycle ergometer, 60-70% heart rate reserve) hypertrophy resistance training (2sets, 10-12 repetitions, 70% of the one-repetition maximum) endurance resistance training (2 sets, 25-30 repetitions, 40% of the one-repetition maximum)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise training
Description: aerobic endurance training (cycle ergometer, 60-70% heart rate reserve) hypertrophy resistance training (2sets, 10-12 repetitions, 70% of the one-repetition maximum) endurance resistance training (2 sets, 25-30 repetitions, 40% of the one-repetition maximum)
Study: NCT03850431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Norms + Behavioral Instructions
Description: A letter with two types of nudges. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring + Consequences for Others + Behavioral Instructions
Description: A letter with three types of nudges. One suggests that the institution cares about the patient. One highlights a potential negative consequence for others if the patient no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring + Consequences for Self + Behavioral Instructions
Description: A letter with three types of nudges. One suggests that the institution cares about the patients. One highlights potential negative consequences for the patient if s/he no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring + Consequences for Others + Consequences for Self + Social Norms + Behavioral Instructions
Description: A letter with all types of nudges combined. One suggests that the institution cares about the patients. One highlights a potential negative consequence for others if the patient no-shows. One highlights potential negative consequences for the patient if s/he no-shows. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
Study: NCT02718482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Docetaxel
Description: Treatment with gemcitabine and docetaxel at day 1 and day 8 n a 3 weeks cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Treatment arm with high doses of ifosfamide continous infusion for 14 days in a 3 weeks cycle
Study: NCT01034657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: LBH589 was supplied at dose strengths of 5 mg or 20 mg hard gelatin capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: LBH589 was supplied at dose strengths of 5 mg or 20 mg hard gelatin capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa
Description: Epoetin alfa was supplied as 10000 IU/1 mL in a ready-to-use syringe.
Study: NCT01797796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06305591
Description: 150 mg PF 06305591 will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.
Study: NCT04508413

Intervention type: OTHER
Group type: OTHER
Intervention: KB295
Description: KB295 is a novel glycan
Study: NCT01638299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypo-Hyper Minimizer (HHM) System
Description: Adjustment of Insulin dosing during meal time
Study: NCT03863301

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided single dose preoperative PBI
Description: A single dose of 20Gy to the gross tumor volume (GTV) is prescribed, to the clinical target volume (GTV + 20mm margin) 15Gy is prescribed.
Study: NCT02565186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: oral tablet
Study: NCT03636269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CR845 0.5 mcg/kg
Description: IV CR845 0.5 mcg/kg administered three times/week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV placebo administered three times/week
Study: NCT02091830

Intervention type: DRUG
Intervention: Paracetamol and nonsteroidal antiinflammatory drug (NSAID)

Intervention type: OTHER
Intervention: Physiotherapy

Intervention type: DRUG
Intervention: Cortisone Injection

Intervention type: OTHER
Intervention: Others
Study: NCT00693732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram treatment
Description: On study inclusion at Visit 2, patients will be successively randomised using a computer generated randomisation list to either placebo or escitalopram (Lundbeck Export A/S, Singapore) 10mg given at bedtime in the first 2 weeks, followed by 20mg in the next 6 weeks. The treatments will be identical in appearance and will be administered in double-blind fashion. Treatment with any anticoagulants, antidiabetics, antimigraine drugs, antispasmodics, analgesics, psychoactive agents including antidepressants, Zelmac®, TCM or acupuncture for IBS and any drugs affecting nociception as judged by investigator are prohibited during the entire study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram treatment
Description: On study inclusion at Visit 2, patients will be successively randomised using a computer generated randomisation list to either placebo or escitalopram (Lundbeck Export A/S, Singapore) 10mg given at bedtime in the first 2 weeks, followed by 20mg in the next 6 weeks. The treatments will be identical in appearance and will be administered in double-blind fashion. Treatment with any anticoagulants, antidiabetics, antimigraine drugs, antispasmodics, analgesics, psychoactive agents including antidepressants, Zelmac®, TCM or acupuncture for IBS and any drugs affecting nociception as judged by investigator are prohibited during the entire study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative sensory testing
Description: Rectal Distention Stimulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing
Description: Rectal Distention Stimulation
Study: NCT04540900

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: KB301
Description: non-integrating HSV-1 vector expressing human type III collagen

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile isotonic saline
Study: NCT02525432

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Infusion
Description: In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the placebo control group will undergo a sham bone marrow harvest and receive a placebo infusion of saline.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous BMMNC Infusion
Description: In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the BMMNC treatment group will undergo a bone marrow harvest and then receive an autologous stem cell infusion.
Study: NCT01797796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capsaicin challenge
Description: 110 mg capsaicin cream (Axsain®) will be applied topically at each visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Capsaicin challenge
Description: 110 mg capsaicin cream (Axsain®) will be applied topically at each visit.
Study: NCT00816660

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII)
Description: Single dose, dose escalation, various cohorts
Study: NCT00610038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glibenclamide
Description: Switching the patients from subcutaneous insulin to oral glibenclamide therapy
Study: NCT00816660

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII)
Description: Single dose, dose escalation, various cohorts

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Marketed plasma-derived VWF/FVIII concentrate
Description: Cross-over: recombinant FVIII (rVWF:rFVIII) and marketed plasma-derived VWF/FVIII concentrate
Study: NCT02912429

Intervention type: DEVICE
Group type: OTHER
Intervention: Patellofemoral Arthroplasty

Intervention type: DEVICE
Group type: OTHER
Intervention: Patellofemoral Arthroplasty
Study: NCT01585792

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01350986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Self-help Workbook + Counseling Telephone Calls
Description: In intervention period of 5 months parents work through 8 cognitive-behavioral self-help booklets (FLOH) and additionally receive 10 counseling telephone calls. Primary purpose of telephone calls is to clarify content of the booklets and support parents in managing their homework assignments accompanied with each booklet. 3 and 6 months after intervention period has ended, two additional booster telephone calls are provided. The booklets are based on the therapy manual Treatment program for children with hyperactive and oppositional problem behavior (THOP) (Döpfner, Schürmann, \& Frölich, 2007) and the parent self-help book Wackelpeter and Trotzkopf: Help for parents of children with hyperkinetic and oppositional behavior (Döpfner, Schürmann, \& Lehmkuhl, 2006).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Directive Self-Help Workbook + Counseling Telephone Calls
Description: In intervention period of 5 months parents are provided 8 non-directive self-help booklets and additionally receive 10 non-directive counseling telephone calls. If the telephone calls are used to clarify content of the booklets or to discuss other child and parenting related topics is at the parents' discretion. Main focus for counselor is to be congruent, empathic and to have unconditional positive regard toward the parents. 3 and 6 months after intervention period has ended, two additional booster telephone calls are provided. The booklets are based on Parent effectiveness training (Gordon, 1970) and Teaching children self-discipline at home and at school (Gordon, 1989).
Study: NCT03915600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quinoa
Description: Personalized diet added with quinoa

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flaxseed
Description: personalized diet added with flaxseed
Study: NCT00415974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health promotion materials on physical activity and nutrition
Description: PACE-PC adolescents and their families will receive information regarding healthy eating and physical activity behaviors on a weekly basis via mail. These behavioral-based materials will educate participants and their families on healthy behaviors that are necessary for successful weight management. Topics will coincide with the intervention goals and include supplemental information to enhance quality of life and improve body image. Topics will include realistic goal-setting and attainment, how to handle holidays and celebrations, eating fast food, grocery shopping and food preparation, and relapse prevention, etc.. Topics will include specific strategies related to the adolescent's readiness to change to reflect processes that are most appropriate. Content from these materials will be addressed by the phone counselors to ensure that participants received and understood intervention messages.
Study: NCT01836458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: Patients will receive KAE609 single dose at a different dose level in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: Patients will receive KAE609 single dose at a different dose level in each cohort.
Study: NCT03066375

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echocardiography-Doppler
Description: Ultrasonographic recordings are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
Study: NCT02698436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acne Mask
Description: The light therapy device contains a combination of red and blue light-emitting diodes. The device is applied once daily, in the evening for a duration of 10 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.5% Benzoyl Peroxide Treatment
Description: The BPO treatment is applied twice daily, once in the morning and once in the evening
Study: NCT03740074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAI
Description: Consenting subjects will be given a Mio Slice, along with instructions on how to utilize the device.~They will register on line with PAI Health, and will be asked to sync their device at least once every 7 days. They will be encouraged to look at the device app on their smart phone at least once daily.~After 1 week of obtaining baseline data, subjects will be encouraged to try to obtain a PAI score of at least 30 initially. Once they obtain a score of 30 consistently, they will be encouraged to increase the score toward 50. If they consistently obtain 50, they can increase their goal sequentially toward a maximum goal of 100. The duration of the study will be 12 weeks.
Study: NCT01807078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: 10 mg p.d. of ezetimibe
Study: NCT01386320

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided ankle block
Description: Under ultrasound guidance, block of the tibial nerve, superficial and deep branches of the common peroneal nerve and saphenous nerves will be carried out using 12 mls 0.5% levobupivacaine and 12 mls 0.75% levobupivacaine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medial forefoot block
Description: Using peripheral nerve stimulator guidance, the tibial and common peroneal nerves will be blocked ( plus the saphenous nerve ), using a total of 12 mls 0.75% levobupivacaine and 12 mls 0.5% levobupivacaine.
Study: NCT00000249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40% N2O
Description: 40% inhaled N2O
Study: NCT01383824

Intervention type: DEVICE
Group type: OTHER
Intervention: Silent™ Hip
Description: A short cementless, femoral component for use in total hip arthroplasty